GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Forward PE Ratio

Genetic Signatures (ASX:GSS) Forward PE Ratio : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Forward PE Ratio?

Genetic Signatures's Forward PE Ratio for today is 0.00.

Genetic Signatures's PE Ratio without NRI for today is 0.00.

Genetic Signatures's PE Ratio for today is 0.00.


Genetic Signatures Forward PE Ratio Historical Data

The historical data trend for Genetic Signatures's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Forward PE Ratio Chart

Genetic Signatures Annual Data
Trend 2020-12 2021-06 2022-02
Forward PE Ratio
38.02 196.08 54.95

Genetic Signatures Semi-Annual Data
2020-06 2020-09 2020-12 2021-03 2021-06
Forward PE Ratio 121.95 34.60 38.02 263.16 196.08

Competitive Comparison of Genetic Signatures's Forward PE Ratio

For the Diagnostics & Research subindustry, Genetic Signatures's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's Forward PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's Forward PE Ratio falls into.



Genetic Signatures Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Genetic Signatures  (ASX:GSS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Genetic Signatures Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.

Genetic Signatures (ASX:GSS) Headlines